News & Updates
Interested in learning more about Hyfe? Read about all of our news, announcements and updates here!
Interested in learning more about Hyfe? Read about all of our news, announcements and updates here!
Comprehensive Chronic Cough Report reveals $15B opportunity. 100M patients, zero FDA-approved drugs, positioning digital cough monitoring as essential pharma infrastructure.
Review including Hyfe research evaluates continuous digital cough monitoring as a practical way to address limitations of patient-reported cough data
Study results demonstrate digital Behavioral Cough Suppression Therapy reduced cough frequency by over 40% in patients with refractory and unexplained chronic cough.
Strategic partnership with KYORIN Pharmaceuticals aims to improve outcomes and expand treatment access to millions impacted by chronic cough globally.
Hyfe’s AI-powered cough monitoring is now available on Actigraph’s FDA-cleared LEAP wearable, enabling continuous, privacy-preserving cough tracking alongside key health biomarkers
Clinical Trial Results Demonstrate Alkaline Magnesium-Based Salt Aerosol Reduced Cough Frequency by up to 35% in Refractory Chronic Cough Patients with Cough Counts Measured Continuously by AI-Powered tech
Hyfe's cough tracker was used in study by University of Navarra, revealing significant variability in cough patterns. This breakthrough highlights potential for continuous, objective chronic cough monitoring.
CoughPro app introduces the world’s first digital Cough Management feature, offering AI-driven solutions for millions suffering from chronic cough.
Research demonstrates the accuracy of Hyfe’s automated cough monitoring process and is the first to observe differences in type and length of cough between men and women.
AI company transitions app to subscription model and adds exclusive new features for users in the UK, Canada, Europe and global users outside the U.S.
Hyfe's technology integrated into ActiGraph’s new FDA-cleared LEAP wearable device that will advance the use of remote patient monitoring in chronic cough clinical research.
Studies show remote patient monitoring technology better predicts cough exacerbations to ultimately improve quality of life and reduce healthcare costs for patients with chronic cough.
Hyfe is expanding into chronic cough treatment with the world's first digital therapeutic for cough, using a proprietary model that combines real time cough frequency with cough suppression therapy.
150 winners selected out of 13,000 private companies; Hyfe recognized for contributions in screening, monitoring and diagnostics technologies
Hyfe has entered into an agreement with Merck, to integrate its artificial intelligence-powered (AI) cough tracker technology into Merck’s consumer disease educational efforts.
Leader in acoustic epidemiology empowers health care providers, researchers, pharmaceutical companies, and patients with cough detection and classification platform
Scientists use Hyfe to confirm that continuous cough monitoring for Long COVID was more sensitive in evaluating cough variability and response to treatment compared to patient reported outcomes.
Dr. Peter Small, Hyfe Chief Medical Officer has delivered deliver an intervention to the G20 Meeting in Yogyakarta, Indonesia, on the role of digital innovation in addressing public health crises.
With apps and artificial intelligence, researchers want to use the cough to better diagnose asthma, Covid-19 and other respiratory illnesses
Accomplished physician, scientist, and product developer to lead Hyfe's efforts as it seeks to transform patient care through cough monitoring and diagnosis.
UNITED STATES – Fast-growing AI Medtech company Hyfe has, today, announced the appointment of world-renowned Seattle-based physician and scientist Dr. Peter Small to the role of Chief Medical Officer. Dr. Small, a passionate advocate for improving patient care through innovative digital solutions, has decades of experience in respiratory medicine, applied research, and the provision of high-tech healthcare worldwide. Hyfe is pioneering acoustic epidemiology, using machine learning algorithms to detect cough to allow patients and providers to unobtrusively monitor cough frequency, providing real-time insights into individual and community health. A global expert in infectious diseases, epidemiology, and global health, Dr. Small will help shape the company’s direction in the coming years, forging partnerships with organizations and individuals to validate and deploy the technology to improve human health. He will also help guide Hyfe’s remote clinical trials as well as promote patient empowerment through remote monitoring of symptoms and more.
Dr. Small has a long history of bringing innovation to health care. Early in his career, he was a medical resident and chief medical resident at UCSF at the dawn of the HIV epidemic. He subsequently joined the faculty of Stanford University Medical School. There, Dr. Small was a pioneer in the field of molecular epidemiology, publishing papers that helped to shape the public health response to the resurgence of tuberculosis.
In 2002, Dr. Small was one of the earliest leaders at the Bill and Melinda Gates Foundation, where he developed their tuberculosis strategy, built the foundation’s core partnerships and country programs, and oversaw a large portfolio of vaccine, drug and diagnostic product development and deployment. In 2011, he relocated to India where he established the foundation’s collaborative tuberculosis program. Subsequently, he joined Stony Brook University as the Founding Director of the University-wide Global Health Institute focused on the use of technology to deliver health care in remote Madagascar and Nepal.
Respiratory diseases are among the leading causes of death and disability in the world. WHO statistics reveal that around 334 million people suffer from asthma worldwide, while millions die prematurely every year from tuberculosis, pneumonia, lung cancer, and other respiratory illnesses. Hyfe was founded in 2020 with the objective to build acoustic tools for respiratory diagnostics and monitoring. In just over a year since its launch, the Hyfe platform is used daily by researchers, medical professionals as well as thousands of regular people all over the world.
Hyfe's technology is built using the world’s largest and fastest growing cough dataset, improved upon continuously via machine learning, and vetted extensively through partnerships with clinical researchers around the worldCommenting on the appointment of Dr. Small as Chief Medical Officer, Hyfe Co-Founder and CEO Joe Brew said:
We are thrilled to welcome Dr. Peter Small to the team as our CMO. This is a very exciting time for Hyfe, and Peter’s decades of experience developing and deploying innovative health solutions globally make him the perfect fit for our capabilities. With Peter onboard, Hyfe is poised to empower patients and providers to remotely monitor health.
Joe Brew
Hyfe Co-Founder
Commenting on joining the team at Hyfe, Dr. Peter Small said:
It’s ironic how much people focus on counting steps while ignoring cough, which is far more consequential. Hyfe is a science-driven company with the technology to make cough count. Particularly now, with increased awareness of cough and the rapid growth of digital health driven by Covid-19, this technology can improve the lives of patients, the care provided by doctors, and the efficiency of health systems
Dr. Peter Small
Hyfe's Chief Medical Officer
Comprehensive Chronic Cough Report reveals $15B opportunity. 100M patients, zero FDA-approved drugs, positioning digital cough monitoring as essential pharma infrastructure.
Review including Hyfe research evaluates continuous digital cough monitoring as a practical way to address limitations of patient-reported cough data
Study results demonstrate digital Behavioral Cough Suppression Therapy reduced cough frequency by over 40% in patients with refractory and unexplained chronic cough.
Strategic partnership with KYORIN Pharmaceuticals aims to improve outcomes and expand treatment access to millions impacted by chronic cough globally.